Chlorzoxazone

Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates FOXO3 phosphorylation and Aβ. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis^{[1][2][3][4][5][6][7][8][9][10]}. In Vitro:Chlorzoxazone (200-1000 μM, 0-24 h) decreases viability and induces [Ca²⁺]i rises in a concentration‑dependent manner in OC2 cells^[2].
Chlorzoxazone (2-20  μM, 4 days) augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation^[3].
Chlorzoxazone (1-30 μM, 30 min) inhibits IL-6 secretion of dendritic cells^[4].
Chlorzoxazone (30 μM) suppresses voltage-dependent L-type Ca²⁺ current in pituitary GH3 cells^[5].
Chlorzoxazone (2.5-80 μM, 24 h) attenuates inflammatory response and amyloidogenesis in the isolated astrocytes and microglial cells with Aβ^[6].
Chlorzoxazone (300 μM) abolishs 4-aminopyridine (HY-B0604)-induced vasoconstriction in rat thoracic aorta^[7].
Chlorzoxazone (600 μM) or 1-EBIO increases Na⁺ absorption across cystic fibrosis airway epithelial cells^[8].
In Vivo:Chlorzoxazone (30-100 mg/kg, p.o., daily, from day 3 following immunization until the end of the experiment) alleviates experimental autoimmune encephalomyelitis in mice^[4].
Chlorzoxazone (25-100 mg/kg, p.o., daily, 4 weeks) attenuates cognitive deficits and neuron death in AD mice^[6].
Chlorzoxazone (20 mg/kg, i.v.; 50 mg/kg, p.o.) is metabolized to OH-CZX via CYP2E1 in rat models of diabetes induced by Alloxan (HY-W017227) or Streptozotocin (HY-13753)^[9].
Chlorzoxazone (10-50 mg/kg, i.p., 20-30 min before onset of access to alcohol) reduces excessive alcohol intake in IAA rats^[10].